|
|
|
|
| LEADER |
04617nma a2201057 u 4500 |
| 001 |
EB002173273 |
| 003 |
EBX01000000000000001311050 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230811 ||| eng |
| 020 |
|
|
|a 9783036576152
|
| 020 |
|
|
|a books978-3-0365-7614-5
|
| 020 |
|
|
|a 9783036576145
|
| 100 |
1 |
|
|a Kircheis, Ralf
|
| 245 |
0 |
0 |
|a The Role of Toll-Like Receptors (TLR) in Infection and Inflammation
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
| 300 |
|
|
|a 1 electronic resource (236 p.)
|
| 653 |
|
|
|a Toll-like receptor (TLR)
|
| 653 |
|
|
|a compression force
|
| 653 |
|
|
|a Omicron
|
| 653 |
|
|
|a TLR8
|
| 653 |
|
|
|a advanced glycation end products (AGEs)
|
| 653 |
|
|
|a LPS
|
| 653 |
|
|
|a virus entry
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a septic shock
|
| 653 |
|
|
|a AKT
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a hepatitis C virus
|
| 653 |
|
|
|a Toll-like receptor
|
| 653 |
|
|
|a glucose
|
| 653 |
|
|
|a cytokines
|
| 653 |
|
|
|a MUC1 (Mucin 1)
|
| 653 |
|
|
|a TLR4-RAGE crosstalk
|
| 653 |
|
|
|a immunotherapy
|
| 653 |
|
|
|a TLR7
|
| 653 |
|
|
|a infection
|
| 653 |
|
|
|a hop
|
| 653 |
|
|
|a 2'-O-ribose-methylation
|
| 653 |
|
|
|a sncRNA
|
| 653 |
|
|
|a SARS-CoV-2
|
| 653 |
|
|
|a COVID-19
|
| 653 |
|
|
|a RNA therapeutics
|
| 653 |
|
|
|a toll-like receptor-2 (TLR2)
|
| 653 |
|
|
|a antiviral agent
|
| 653 |
|
|
|a nucleolin
|
| 653 |
|
|
|a CD14
|
| 653 |
|
|
|a spike protein
|
| 653 |
|
|
|a lipopolysaccharide (LPS)
|
| 653 |
|
|
|a broad-spectrum
|
| 653 |
|
|
|a human PDL
|
| 653 |
|
|
|a TLR7 (Toll-like receptor 7)
|
| 653 |
|
|
|a RNase T2
|
| 653 |
|
|
|a endocytosis
|
| 653 |
|
|
|a TLR
|
| 653 |
|
|
|a diabetes
|
| 653 |
|
|
|a immunoregulation
|
| 653 |
|
|
|a antiviral
|
| 653 |
|
|
|a alveolar macrophages
|
| 653 |
|
|
|a inflammatory
|
| 653 |
|
|
|a TLR4
|
| 653 |
|
|
|a immune activation
|
| 653 |
|
|
|a aquaporin-3 (AQP3)
|
| 653 |
|
|
|a polymorphism
|
| 653 |
|
|
|a oligonucleotide
|
| 653 |
|
|
|a monoclonal antibody TLR4
|
| 653 |
|
|
|a skin
|
| 653 |
|
|
|a aluminum adjuvant
|
| 653 |
|
|
|a MAPKs
|
| 653 |
|
|
|a tumor vaccine
|
| 653 |
|
|
|a sepsis
|
| 653 |
|
|
|a keratinocytes
|
| 653 |
|
|
|a sterile inflammation
|
| 653 |
|
|
|a immune system
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a NF-kappaB
|
| 653 |
|
|
|a cytokine storm
|
| 653 |
|
|
|a innate immunity
|
| 653 |
|
|
|a histone deacetylase inhibitor
|
| 700 |
1 |
|
|a Planz, Oliver
|
| 700 |
1 |
|
|a Kircheis, Ralf
|
| 700 |
1 |
|
|a Planz, Oliver
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-0365-7614-5
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/7355
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/100889
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 140
|
| 520 |
|
|
|a Toll-like receptors (TLRs) represent a powerful system for the recognition and elimination of pathogen-associated molecular patterns (PAMPs) from bacteria, viruses, and other pathogens and damage-associated molecular patterns (DAMPs) released from dying cells. Typical PAMPs include bacterial cell wall components, viral pathogens, or pathogenic nucleic acids, including viral RNA and DNA. Activation of TLRs leads to the production of proinflammatory cytokines and type I interferons which are important for the induction of the host immune response against bacterial and viral infections. However, dysregulation and overstimulation can be detrimental, leading to hyper-inflammation, sepsis, and loss of tissue integrity. The involvement of TLRs in inflammation and bacterial infection has been recognized for a long time. There is an increasing number of reports demonstrating the involvement of TLR activation in a variety of viral infections, associated with protective immunity, but also immune hyper activation and even viral replication. Recent data show the involvement of TLR activation in various acute respiratory viral infections, including SARS-CoV-2 and indicate an essential role in COVID-19 pathology. It aimed to gather newest data and hypotheses regarding molecular and cellular mechanisms of TLR triggering and activation and their downstream signaling pathways by viral infections, and their correlation to immunology and pathophysiology of the associated diseases, to facilitate translational research resulting in new targets for the treatment of viral infectious diseases including COVID-19.
|